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Purpose. To evaluate the eﬀects of photodynamic therapy (PDT) combined with intravitreal injection of ranibizumab (IVR) for
exudative age-related macular degeneration (AMD). Methods. Retrospective case series. Thirty eight eyes of 38 patients with
exudative AMD underwent combined therapy consisting ﬁrst of IVR, followed by PDT within a week and the second IVR at 1
month. All patients were followed up for more than 12 months. The best corrected visual acuity (BCVA) and central macular
thickness (CMT) were examined. Results. The mean number of IVR and PDT sessions were 2.9 ± 1.3 and 1.1 ± 0.3, respectively.
The mean BCVA and CMT were signiﬁcantly improved to 0.38 logMAR units (P<0.01) and 240µm( P<0.01) at 12 months,
respectively. Thirty-six of 38 eyes (94.8%) improved or maintained BCVA at 12 months. Conclusion. PDT combined with IVR for
exudative AMD was eﬀective at improving visual acuity and CMT with a low recurrence rate for 12 months.
1.Introduction
Age-related macular degeneration (AMD), especially exuda-
tive AMD is a major cause of visual disability and blindness
[1]. Photodynamic therapy (PDT) has been shown to oc-
clude the neovascular membrane and decrease visual acuity
loss in exudative AMD [1, 2]. However, several studies have
shown that PDT causes damage to the physiological chorio-
capillary layer, and that repeated PDT therapy often leads to
occlusion of the choriocapillaris [2, 3].
Recently, monthly intravitreal injection therapy of anti-
vascular endothelial growth factor (VEGF) antibody has
been shown to increase visual acuity in exudative AMD [4–
7]. Because the pathogenesis of choroidal neovascularization
(CNV) is complex and exudative AMD is a multifactorial
disease, combined therapy adopting diﬀerent mechanisms
to inhibit and destroy CNV, namely, PDT and anti-VEGF
antibodytherapy,mayfacilitateimprovementofvisualacuity
on exudative AMD.
Husain et al. reported that PDT combined with intrav-
itreal injections of ranibizumab showed a greater reduction
of ﬂuorescein leakage compared to PDT only in monkey eyes
[8]. Several clinical studies have shown that a combination
therapy of PDT and ranibizumab eﬀectively reduced the
number of intravitreal injections compared to anti-VEGF
antibody monotherapy regimens [9–13].
In this study, we examined eﬃcacy of PDT combined
with intravitreal injections of ranibizumab (IVR) in patients
with exudative AMD and compared results of typical AMD
and polypoidal choroidal vasculopathy (PCV).
2.MaterialsandMethods
Thirty-eight eyes of 38 consecutive Japanese patients (29
men, 9 women) who were diagnosed with exudative AMD
without previous treatment at Toyama University Hospital
between April and December 2009 were enrolled in this
study. The study was conducted in accordance with the2 Journal of Ophthalmology
Institutional Guidelines of the University of Toyama and was
approved by the Institutional Review Board. The procedures
conformed to the tenets of the World Medical Association’s
Declaration of Helsinki.
The inclusion criteria for this study were patient age
older than 50 years, exudative AMD in the macular area,
decimal best-corrected visual acuity (BCVA) of 0.7 or worse,
and a greatest linear dimension (GLD) of 5400-µm or less.
The exclusion criteria were CNV caused by other diseases,
previously received subfoveal laser treatment, verteporﬁn
photodynamic therapy, or experimental treatments for exda-
tive AMD. Patients who had uncontrolled hypertension, a
recent myocardial infarction, or cerebral vascular accidents
were also excluded.
Before the initial treatment, all patients underwent base-
line ophthalmic examinations, which included decimal
BCVA, fundus examination, optical coherence tomography
(OCT) using an RTVue-100 (Optovue Inc., Fremont, Calif,
USA), ﬂuorescein angiography (FA), and indocyanine green
angiography (ICGA).
All patients were followed up for more than 12 months.
At each visit, a fundus examination, BCVA, and OCT were
performed. FA and ICGA were performed when recurrence
ofleakagewassuspectedbyOCTandclinicalﬁndingsduring
the followup examinations.
Patients received one intravitreal injection of 0.5mg
ranibizumab (IVR), followed by PDT within a week after the
ﬁrst IVR. This treatment schedule was followed by Sato et
al. [14]. A standard-ﬂuence verteporﬁn PDT was performed
at an infusion dosage of 6mg/m2. Application of a 689-
nanometerlaseratadoseof50J/cm2 wasstarted15minafter
the start of verteporﬁn infusion using a Visulas PDT system
690S (Carl Zeiss Meditec AG, Jene, Germany). A second IVR
was given to all eyes at 4 weeks after the ﬁrst IVR.
Additional treatments were determined by BCVA, CMT,
and FA with ICGA. The retreatment criteria for IVR were
as follows; (1) decrease of BCVA by more than 0.1 logMAR
unit, (2) more than 100-µm of increase in central macular
thickness (CMT), (3) the presence of subretinal ﬂuid or
intraretinal edema at the fovea on OCT, (4) new sub- or
intraretinal hemorrhage, or (5) signs of active CNV leakage
on ﬂuorescein angiography. These retreatment criteria were
referred to the TROPEDO trial [12]. If the CNV was
increased in size or relapsed, additional PDT was performed.
We calculated GLD in each eye based on the ﬁndings of
FAforPDTtreatment.Incaseofpolypoidal choroidalvascu-
lopathy (PCV), ICGA was utilized for GLD calculation. The
sizes of GLD were divided into 3 groups; GLD 1800µm,
GLD between 1801 and 3500µm, and GLD between 3501
and 5400µm group. We evaluated BCVA and CMT in GLD
groups.
CMT was manually measured at the fovea with OCT
images.Wealsoevaluatedthejunctionlinebetweentheinner
and outer segments of the photoreceptors (IS/OS) beneath
the fovea at baseline and 12 months with OCT images.
We used a grading scale reported by Mitamura et al. [15].
IS/OS was categorized into 3 grades, which were grade 0
(invisible IS/OS line), grade 1 (abnormal or discontinuous
IS/OS line), and grade 2 (normal or well-preserved IS/OS
Table 1: Treatments during 12 months.
Mean PDT sessions 1.1 ±0.3 (1-2)
Mean IVR 2.9 ±1.3 (2–6)
Total number of combined treatments
1 PDT + 2 IVR 22 (57.9%)
1 PDT + 3–5 IVR 11 (28.9%)
2 PDT + 4–6 IVR 5 (13.2%)
IVR: intravitreal injection of ranibizumab, PDT: photodynamic therapy.
line). Improvement of BCVA was deﬁned as a decrease of
more than 0.3 logMAR units, and deterioration of BCVA was
deﬁned as an increase of more than 0.3 logMAR units.
Hypoperfusion of the choriocapillaris caused by PDT
was evaluated with ICGA at 3 months after the ﬁrst PDT
according to a grading scale by Michels et al. [16].
Statistical analyses were performed with JMP 9 (SAS
Institute, Cary, NC, USA). Data analyses included a paired
t-test, nonparametric correlation analysis (Spearman), and
one-factor analysis of variance (ANOVA). P values less than
0.05 were considered statistically signiﬁcant.
3. Results
3.1. Baseline Characteristics and Followup. The mean age of
the 38 patients (mean ± standard deviation) was 72.4 ± 8.9
years (range: 53–90 years). The mean followup term was
14.0±1.7 months (range: 12–17 months). Based on ﬁndings
of FA and ICGA at baseline, lesion types of CNV of 38
eyes were divided into 10 eyes (26.3%) of predominantly
classic CNV, 6 eyes (15.8%) of minimally classic CNV, 8 eyes
(21.1%) of occult CNV, and 14 eyes (36.8%) of polypoidal
choroidal vasculopathy (PCV).
According to the GLD size, 24 eyes of typical AMD were
divided into 10 eyes of the group of GLD 1800µm, 11 eyes
of the group of GLD between 1801 and 3500µm, and 3 eyes
of the group of GLD between 3501 and 5400µm. Fourteen
eyes of PCV were divided into 5 eyes of the group of GLD
1800µm, 5 eyes of the group of GLD between 1801 and
3500µm, and 4 eyes of the group of GLD between 3501 and
5400µm.
Each patient received an average of 1.1 ± 0.3( r a n g e :
1-2) sessions of PDT and 2.9 ± 1.3 (range: 2–6) IVR
during 12-month followup (Table 1). Twenty-two of 38 eyes
(57.9%) were suﬃciently healed by the initial treatment with
a single PDT and two IVR. Sixteen of 38 eyes (42.1%)
underwent an additional one- to- four IVR. Five of 38 eyes
(13.2%)requiredanotherPDTsession.OncetheCNVlesion
achieved scarred by one or two PDT sessions combined
with 2- to- 6 IVR, a recurrence of exudative changes at the
fovea was detected in 4 eyes (10.5%) during the 12-month
followup (Table 2). As a retreatment for these 4 recurrent
eyes, 1 eye underwent additional IVR and 3 eyes underwent
another PDT session with IVR.
3.2. Visual Acuity. Mean BCVA of all 38 eyes was 0.58 ±0.40
logMAR units at baseline, 0.47±0.40 at 1 month, 0.33±0.28
at 3 months, 0.35 ± 0.38 at 6 months, and 0.38 ± 0.39 at 12Journal of Ophthalmology 3
Table 2: Recurrence rates of exudative changes after successful ini-
tial treatment.
Initial treatment Eyes (%) Recurrence eyes (%)
1 PDT + 2 ranibizumab 23 (60.5%) 1 (4.3%)
1 PDT + 3 ranibizumab 9 (23.7%) 2 (22.2%)
1 PDT + 4 ranibizumab 2 (5.3%) 1 (50.0%)
1 PDT + 5 ranibizumab 2 (5.3%) 0 (0.0%)
2 PDT + 6 ranibizumab 2 (5.3%) 0 (0.0%)
Total 38 eyes 4 eyes (10.5%)
PDT: photodynamic therapy.
months. Mean BCVA was signiﬁcantly improved at 1, 3, 6,
and12months,comparedwiththebaseline(P<0.01,resp.).
Figure 1 shows the changes in visual acuity according to
GLD groups. In all 3 groups, the mean BCVA was improved
at 3 and 6 months after the combined therapy, compared
with the baseline (Figure 1(a)). The group of GLD 
1800µm showed better BCVA than groups of GLD between
1801 and 3500µm and GLD between 3501 and 5400µma t
all time points, however, no statistically signiﬁcant diﬀerence
was detected among the three groups (P>0.05, Figure 1(a)).
As shown in Figure 1(b), the group of GLD  1800µm
showed better mean BCVA than the other 2 groups in the
eyes with typical AMD. Mean BCVA of the group of GLD
 1800-µm was signiﬁcantly improved at 1, 3, 6, and 12
months (P<0.01), compared with the baseline. However,
no statistical diﬀerence was detected among the 3 groups. As
shown in Figure 1(c), the group of GLD  1800µm showed
better mean BCVA than the other 2 groups in the eyes with
PCV, however, no statistical diﬀerence was also detected.
Table 3 showed changes in BCVA from the baseline in
all 38 eyes during 12 months. The number of eyes with
improved or stable BCVA at 12 months compared with the
baseline was 36 (94.7%). The visual acuity of the remaining
2 eyes (5.3%) had deteriorated more than 0.3 logMAR units
at 12 months. Reasons for the decreased visual acuity of
these 2 eyes were the movement of subretinal hemorrhage
to beneath the fovea in 1 eye of PCV and the recurrence of
subfoveal CNV at 11 months in 1 eye.
3.3. Central Macular Thickness. The mean CMT of all 38
eyes was 414±120 µm at baseline, 279 ± 126µm at 1 month,
225 ± 74µm at 3 months, 247 ± 120µm at 6 months, and
240 ± 91µm at 12 months. The mean CMTs at 1, 3, 6, and
12 months were signiﬁcantly decreased compared with the
baseline (P<0.01, resp.).
Changes in the mean CMT of 38 eyes of the 3 GLD
groups were shown in Figure 2(a). All groups signiﬁcantly
decreased the mean CMT after the combined therapy (P<
0.01) and showed similar mean CMTs among the 3 groups
after 3 months. There was no signiﬁcant diﬀerence among
the 3 groups. As shown in Figure 2(b), the mean CMT in the
eyes with typical AMD signiﬁcantly decreased after 1 month
inthegroupsofGLD 1800µmandGLDbetween1801and
3500µm( P<0.01, P<0.05), compared with the baseline.
However, the mean CMT in the group of GLD between 3501
and 5400µm did not signiﬁcantly decrease compared with
the baseline. As shown in Figure 2(c), the mean CMT in
the eyes with PCV was signiﬁcantly decreased at 1, 3, and
12 months (P<0.05) in the groups of GLD  1800µm
and GLD between 1801 and 3500µm, compared with the
baseline. However, there was no signiﬁcant diﬀerence in the
changes of mean CMT in the group of GLD between 3501
and 5400µm.
3.4. IS/OS Line. Figure 3 showed scatter plots of BCVA at
baseline and 12 months in 3 gradesof IS/OSline. Atbaseline,
IS/OS line was evaluated in OCT images of 38 eyes, which
weredivided into 16 eyes (42.1%) of grade 0 of IS/OS line, 20
eyes (52.6%) of grade 1 of IS/OS line, and 2 eyes (5.3%) of
grade 2 of IS/OS line (Figure 3(a)). At 12 months, IS/OS line
w a se v a l u a t e di nO C Ti m a g e so f2 8e y e s ,w h i c hw e r ed i v i d e d
into 8 eyes (28.6%) of grade 0, 14 eyes (50.0%) of grade 1,
and 6 eyes (21.4%) of grade 2 (Figure 3(b)). The grades of
IS/OS line negatively correlated with BCVA at baseline and
12 months (P<0.01), respectively. There was no signiﬁcant
correlation between the grades of IS/OS line at baseline and
BCVA at 12 months.
3.5. Adverse Events and Complications. ICGA was performed
in 31 of 38 eyes at 3 months to evaluate choroidal hypoper-
fusion according to a grading scale used in a previous study
[16]. Among 31 eyes, 4 (12.9%) showed no eﬀect on the
choriocapillaris in early or late ICGA (grade 0), 13 (41.9%)
showed mild (not signiﬁcant) nonperfusion in early ICGA
(grade I), 11 (35.5%) showed moderate nonperfusion in
early ICGA (grade II), and 3 (9.7 %) showed signiﬁcant
nonperfusion in early ICGA (grade III).
There were no ocular complications such as endoph-
thalmitis, sustained ocular pressure increase, or subretinal
hemorrhage. No systemic side eﬀects related to treatment
were encountered in this study.
4. Discussion
Combined therapy of PDT and ranibizumab for CNV
secondary to exudative AMD has been examined by several
groups and has been shown to improve visual acuity and to
reduce the number of intravitreal injections of ranibizumab
compared to ranibizumab monotherapy [5–7, 9–13]. With
combined therapy of PDT and ranibizumab, we showed
that the mean visual acuity was signiﬁcantly improved from
0.58 ± 0.40 to 0.38 ± 0.39 logMAR units at 12 months and
that the BCVA of 36 of 38 eyes (94.7%) was improved or
maintained from the baseline at 12 months. The mean CMT
wassigniﬁcantlyimprovedfrom414±120µmto240±91µm
at 12 months. The TORPEDO trial, which examined the
eﬀects of combined PDT and ranibizumab injection on the
same day, showed that the mean visual acuity improved by
7.2 letters and 84% of the patients had stable or improved
vision at 2 years [12]. It also showed that the mean CMT
decreased by 146µm[ 12]. These results were comparable to
ours although diﬀerences in study design and sample size
prohibited direct comparison.4 Journal of Ophthalmology
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Figure 1: Changes in mean best corrected visual acuity (BCVA). Visual acuity was expressed as the logarithm of minimal angle of resolution
(logMAR). (a) Mean BCVA of all 38 patients in three GLD groups; GLD  1800µm, GLD between 1801 and 3500µm, and GLD between
3501 and 5400µm. The group of greatest linear dimension (GLD)  1800µm showed better BCVA than those of the other 2 groups at all
time points. However, there was no signiﬁcant diﬀerent among the 3 groups (P>0.05). (b) Mean BCVA of typical AMD of 24 patients in
three GLD groups. (c) Mean BCVA of PCV of 14 patients in 3 GLD groups. Bars indicate standard deviations. ∗P<0.05, ∗∗P<0.01; P value
for comparison between baseline and each visit. AMD: age-related macular degeneration, PCV: polypoidal choroidal vasculopathy.
Table 3: Changes in visual acuity after PDT combined with IVR during 12 months.
Changes in logMAR from the baseline 1 month 3 months 6 months 12 months
0.3 logMAR units improvement 7 eyes (18.4%) 16 eyes (42.1%) 14 eyes (36.8%) 15 eyes (39.5%)
Changes under 0.3logMAR units 30 eyes (78.9%) 21 eyes (55.3%) 23 eyes (60.5%) 21 eyes (55.3%)
0.3 logMAR units deterioration 1 eye (2.6%) 1 eye (2.6%) 1 eye (2.6%) 2 eyes (5.3%)
IVR: intravitreal injection of ranibizumab, PDT: photodynamic therapy.Journal of Ophthalmology 5
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Figure 2: Changes in mean central macular thickness (CMT). (a) Mean CMT of all 38 patients in three GLD groups; GLD  1800µm, GLD
between 1801 and 3500µm, and GLD between 3501 and 5400µm. All 3 groups showed similar values among the 3 groups at all time points.
(b) Mean CMT of typical AMD of 24 patients. (c) Mean CMT of PCV of 14 patients in 3 GLD groups. There was no signiﬁcant diﬀerence
among the three groups (P>0.05). Bars indicate standard deviations. ∗P<0.05, ∗∗P<0.01; P value for comparison between baseline and
each visit. AMD: age-related macular degeneration, GLD: greatest linear dimension. PCV: polypoidal choroidal vasculopathy.
We showed that 57.9% of the patients with exudative
AMD successfully achieved scarring without further treat-
ments by a single PDT and 2 IVR during 12 months. Only 4
eyes (10.5%) in this study showed a recurrence of exudative
changes. Mataix et al. reported that 39.6% of patients were
successfully treated with only a single initial dose (PDT and
ranibizumab) and remained stable for12 months [10].Thus,
combined treatment of PDT and IVR might be suﬃcient to
scartheCNVlesioninabouthalfofexudativeAMDpatients.
In the FOCUS study, the patients received standard-
ﬂuence PDT on an as-needed basis along with monthly
ranibizumab injections. As a result, the mean sessions of
PDT was 1.32 and 90.5% of the patients had maintained
or improved visual acuity at 1 year [9]. In our study, the
mean sessions of PDT was 1.1 and 94.7% of the patients
maintained or improved their visual acuity at 1 year.
Ranibizumab monotherapy for exudative AMD required
5.2 ± 2.8 IVR during a followup of 12 ± 4.3 months when6 Journal of Ophthalmology
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Figure 3:Scatter plotsshowingcorrelationsbetweenvisualacuityandgradesoftheinnerandoutersegmentsofthephotoreceptors(IS/OS).
Visual acuity was expressed as the logarithm of minimal angle of resolution (logMAR). (a) Scatter plot at baseline. There was a signiﬁcant
negative correlation between visual acuity at baseline and IS/OS grade at baseline (Speaman correlation coeﬃcient [rs] =− 0.429;P<0.01).
(b) Scatter plot at 12 months. There was a signiﬁcant negative correlation between visual acuity at 12 months and IS/OS grade at 12months
(rs =− 0.687;P<0.01).
ranibizumab monotherapy was performed on an as-needed
basis [13]. Mataix et al. showed results of combined therapy
of PDT and ranibizumab: in that study, 92.3% patients
s h o w e di m p r o v e dv i s i o no ra tl e a s ta v o i d e dm o d e r a t el o s s
of vision over 1 year with 1.22 PDT sessions and 2.37IVR
[10]. Their results were similar to our results even though
they performed IVR within 48 to 60 hours after PDT. By
combined therapy with PDT, we could limit the number of
IVR to 2.9 ±1.3 injections per patient during 12 months.
Our protocol of the primary therapy consisted of 2IVR
and a single PDT. We performed the ﬁrst IVR one week
before PDT. The reasons why IVR was preceded to PDT
were as follows. (1) In case that a bacterial endophthalmitis
is occurred after IVR within a week, the patient must
immediately need intensive antibacterial treatments. (2)
Preceding IVR is reasonable to quench VEGF in the retina
and the choroid after application of PDT, which was shown
to induce VEGF production [17]. Sato et al. reported
beneﬁcial eﬀects on PCV with a combined therapy of
intravitreal injection of 1.25mg bevacizumab 1 week before
PDT [14]. Kaiser suggested that the intravitreal injection
of bevacizumab before PDT might have beneﬁcial eﬀects
on the retreatment rate in the combined therapy for AMD
[18]. They showed lower retreatment rates after combined
therapy in patients who received intravitreal bevavizumab
before PDT compared to those who received PDT ﬁrst or
intravitreal bevacizumab and PDT on the same day [18].
Moutray et al. reported the relationships between GLD
and visual functios in patients with exudative AMD. They
showed GLD and visual acuity signiﬁcantly correlated with
each other [19]. Arias et al. examined the lesion size on
photodynamic therapy with verteporﬁn of predominantly
classic lesions [20]. They reported that the group of smaller
lesions had more improvements with one or more lines of
visual acuity compared with the larger lesion groups. In this
study, we showed a similar tendency in the improvement
of mean BCVA of all eyes, typical AMD, and PCV. The
smallest GLD group showed better mean BCVA during 12
months although there was no signiﬁcant diﬀerence among
the 3 groups of GLD. The mean CMT showed a signiﬁcant
decrease in all 3 groups of GLD during 12 months, but there
was no statistical diﬀerence among the 3 groups of GLD. The
mean CMT did not show a clear tendency according to the
GLD size.
Several studies reported that the presence of a normal
IS/OS junction indicated normal functions of photorecep-
tors and the grades of IS/OS line correlated with visual acuity
[21, 22]. We showed that grades of IS/OS line signiﬁcantly
correlated with the BCVA at baseline and 12 months,
respectively. Better IS/OS line indicated better visual acuity,
however, grades of IS/OS line at baseline did not correlate
with the BCVA at 12 months. The grade of IS/OS was not
shown a predictive factor of BCVA in this study.
We also examined choroidal hypoperfusion with ICGA
at 3 months after combined therapy of PDT and IVR.
Fourteen of 31 eyes (45.2%) showed moderate (grade II) or
signiﬁcant (grade III) nonperfusion in early ICGA. Iriyama
et al. showed that standard-ﬂuence PDT (50J/cm2) caused
a signiﬁcant loss of choriocapillary perfusion in 40.9% of
the patients [23]. Michels et al. showed that 60% of patients
treated with standard-ﬂuence PDT (50J/cm2)h a dm o d e r a t e
or signiﬁcant choroidal nonperfusion changes in early ICGA
at 3 month [16]. In this study, we did not examine changes in
choroidal hypoperfusion between 3 months and 12 months.Journal of Ophthalmology 7
Further studies are needed to examine eﬀects of lower ﬂu-
ences of PDT on choroidal hypoperfusion and eﬀects of
ranibizumab on lasting periods of choroidal hypoperfusion.
Combined therapy of IVR and PDT seemed eﬀective
on both typical AMD and PCV for a short term, however,
randomized clinical trials are needed to show which combi-
nationofIVRwithPDTisthemosteﬀectivefortypicalAMD
and PCV on improvements of visual functions over the long
term.
5. Conclusions
PDT combined with IVR showed a siginiﬁcant improvement
in visual acuity and in CMT for exudative AMD of Japanese
patients with low recurrence rates for 12 months. Grades
of IS/OS line was signiﬁcantly correlated with visual acuity.
Further studies with longer followup periods are necessary
to assess treatment safety and eﬃcacy.
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